Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook

PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.

Scroll to Top